Foundayo goes on sale in the United States

Eli Lilly said Foundayo (orforglipron), a once-daily GLP-1 pill for weight management, is now available in the United States through LillyDirect, telehealth providers and retail pharmacies nationwide, starting April 9, 2026 ^[1]. The launch follows the drug's FDA approval on April 1 for adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and more physical activity ^[3].

Lilly said prescriptions were accepted through LillyDirect immediately after approval, with shipping beginning April 6 and broader pharmacy and telehealth availability shortly after ^[3]. The company is pricing the pill at $149 a month for self-pay patients at the lowest dose ^[1]. People with commercial insurance that covers Foundayo may pay as little as $25 a month using the company's savings card, and Lilly says eligible Medicare Part D patients may be able to get it for $50 a month beginning July 1, 2026 ^[1][3].

Early prescriptions lag the Wegovy pill

The commercial start has been slower than many investors expected. IQVIA data cited by Jefferies analysts showed 1,390 Foundayo prescriptions in its first week on the market and 3,707 in the second week ^[2]. By comparison, Novo Nordisk's oral Wegovy (semaglutide) logged more than 3,000 prescriptions in the first few days after its January launch and 18,410 in its second week ^[2]. Lilly shares fell almost 4% after the data was reported, though the stock has risen strongly over the past 12 months on sales growth for Zepbound and Mounjaro (both tirzepatide) ^[2].

One caveat in the data: demand for the Wegovy pill may have been boosted by pent-up interest in the first oral alternative to weekly injections, a factor that was likely weaker by the time Foundayo arrived in April ^[2].

What the trials showed

Foundayo's approval rests on the ATTAIN program, which enrolled more than 4,500 people with obesity or overweight across two 72-week registration trials ^[1]. In ATTAIN-1, which randomized 3,127 participants without diabetes, people on the highest dose who stayed on treatment lost an average of 27.3 pounds, or 12.4% of body weight, versus 2.2 pounds (0.9%) on placebo ^[1][3]. Counting everyone assigned to the drug regardless of whether they finished, average loss was 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo ^[1][3]. Lilly also reported reductions in waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses ^[1].

The label carries a boxed-type warning that Foundayo may cause thyroid tumors, including thyroid cancer, and it should not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2 ^[1]. The most common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, gas and hair loss ^[1]. Lilly also says Foundayo should not be used with other GLP-1 receptor agonist medicines, and that oral birth control pills may not work as well while taking it, with providers possibly recommending another method for 30 days after starting and after each dose increase ^[1].

The sources describe the drug-interaction language somewhat differently. Lilly's own materials frame the birth control issue as a conversation with a prescriber ^[1], while pharmaphorum, summarizing Novo Nordisk's competitive messaging, says the label includes restrictions on use alongside oral birth control and the cholesterol drug simvastatin ^[2].

Why it matters for patients

The practical difference between the two pills is how they are taken. Lilly is emphasizing that Foundayo can be taken any time of day with no food or water restrictions, while the Wegovy pill must be taken first thing in the morning on an empty stomach, 30 minutes before eating or drinking ^[1][2]. Novo Nordisk is countering with brand recognition, a claimed weight-loss edge, the Foundayo label restrictions, and the cardiovascular risk-reduction approval for injectable semaglutide ^[2].

Coverage remains the bigger variable. Lilly notes that about half of Americans with employer-sponsored insurance lack coverage for obesity medications ^[1], which is why the $149 self-pay tier matters for people paying cash. Whether the $149 price applies beyond the lowest dose is not spelled out in the sources, and pricing for higher doses is not yet known.

What happens next

Lilly reports first-quarter results on April 30 and Novo Nordisk on May 6, which should give a fuller picture of oral GLP-1 uptake and any effect on injectable Wegovy and Zepbound ^[2]. The Medicare Part D $50 option is slated to begin as soon as July 1, 2026 ^[1]. Lilly has filed orforglipron for weight management and/or type 2 diabetes in more than 40 countries ^[3].